Market Research Industry Today
Chemiluminescence Immunoassay Market: Regional Growth, Challenges, and Forecast with CAGR 7.8% by 2030 | Abbott Laboratories, Beckman Coulter Inc., BioMerieux, Randox Laboratories Ltd.
According to a research report "Chemiluminescence Immunoassay Market”, by Product (Analyzers {Fully-automated, Semi-automated}, Reagents {Luminophore Markers, Enzymatic Markers}, Consumables), Application (Endocrine Disorders, Oncology, Infectious Diseases, Hepatitis & Retrovirus, Cardiovascular Disorders, Allergy, Autoimmunity, Drug Discovery & Development, Others), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biological Industries, Others), & Region - Global Forecast to 2030.
Chemiluminescence Immunoassay Market Scope:
- Market size value in 2023 - USD 11.43 Billion
- Market size value in 2030 - USD 19.34 Billion
- CAGR (2023-2030) - 7.8%
- Forecast Period - 2023-2030
- Historic Data - 2019
- Segments Covered - Product, Application, End User & Region
- Geographies Covered - North America, Europe, Asia Pacific, and RoW
- Sample of Companies Covered - Immunodiagnostic Systems, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Ortho Clinical Diagnostics, Randox Laboratories Ltd.
Download Sample Pages - https://www.marketdigits.com/request/sample/3659
Browse in-depth TOC on "Chemiluminescence Immunoassay Market"
- 144 - Tables
- 99 - Figures
- 362 - Pages
Market Overview: The Chemiluminescence Immunoassay (CLIA) Market is witnessing substantial growth, driven by its widespread application in detecting chronic diseases such as infectious diseases, autoimmune disorders, cardiovascular issues, diabetes, obesity, and cancer. Beyond clinical applications, CLIA is also utilized for therapeutic drug monitoring by pharmaceutical companies and research institutes. Chemiluminescence immunoassay (CLIA) solutions find extensive applications in detecting a range of chronic diseases, including infectious diseases, autoimmune conditions, cardiovascular issues, diabetes, obesity, and cancer. Pharmaceutical companies and research institutes leverage CLIA for therapeutic drug monitoring purposes. The market is significantly influenced by the growing emphasis on early chronic disease diagnosis and heightened pharmaceutical industry engagement in drug discovery and development activities. These factors are identified as impactful drivers contributing to the market's growth.
Market Dynamics
Drivers:
- Growing demand for point-of-care testing
- High prevalence of hematologic diseases
- Increasing awareness of early detection and treatment
Opportunities:
- Integration of CLIA with other technologies
- Development of CLIA assays for emerging infectious diseases
- Advancements in CLIA technology
North America dominates the market for Chemiluminescence Immunoassay.
North America secured the leading market share, and is projected to maintain its dominance throughout the forecast period. This regional stronghold can be attributed to factors such as the well-established healthcare infrastructure, widespread adoption of advanced Chemiluminescence Immunoassay (CLIA) solutions, and a rising incidence of chronic diseases. The U.S., in particular, benefits from enhanced accessibility to innovative CLIA systems, the presence of key industry players like Abbott Laboratories, Beckman Coulter, Inc., DiaSorin, and Roche. These factors collectively contribute to the sustained growth of the CLIA market in North America.
With the highest market share, the United States is a dominant player, driven by a growing population grappling with cardiovascular diseases and other chronic conditions. According to the latest data from the Centers for Disease Control and Prevention (CDC) in February 2022, emergency room visits attributed to coronary artery disease, ischemic heart disease, or a history of myocardial infarction constitute 7.2% of current cases. Additionally, CDC data from January 2022 reveals that there were 432,000 emergency department visits in the previous year where stroke was the primary diagnosis. These statistics underscore the significant healthcare burden posed by cardiovascular issues in the United States, contributing to the nation's leading position in the market.
Asia pacific is the fastest-growing region for the Chemiluminescence Immunoassay Market. Awareness of chronic diseases in emerging economies like China and India. Additionally, the rising acceptance of Chemiluminescence Immunoassay (CLIA) systems, coupled with the introduction of innovative CLIA systems by local entities, is expected to contribute to the regional market's development. A noteworthy example is the launch of the CL-6000i CLIA analyzer by Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a prominent Chinese medical device manufacturer, at the China International Medical Equipment Fair in 2018. This event underscores the dynamic growth potential of the CLIA market in the Asia Pacific region.
Top Key Players covered in the market report:
- Abbott Laboratories
- Beckman Coulter Inc.
- BioMerieux
- DiaSorin S.p.A, F. Hoffmann-La Roche AG
- Immunodiagnostic Systems
- Inova Diagnostics, Inc.
- Maccura Biotechnology Co., Ltd.
- Ortho Clinical Diagnostics
- Randox Laboratories Ltd.
- Roche Holding AG
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens Healthineers
- Sysmex Corporation
- Tosoh Corporation
For More Information - Inquire Now!
Segmentations Analysis of Chemiluminescence Immunoassay Market: -
- By Product
- By Application
- By End User
- By Region
About us:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.
Contact Us: Email: sales@marketdigits.com
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
